Graham, Robert J.
Darras, Basil T.
Haselkorn, Tmirah
Fisher, Dan
Genetti, Casie A.
Miller, Weston
Beggs, Alan H. http://orcid.org/0000-0001-8818-0568
Funding for this research was provided by:
Astellas Gene Therapies
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR044345)
Muscular Dystrophy Association (MDA602235)
Joshua Frase Foundation
Article History
Received: 18 November 2022
Accepted: 14 May 2023
First Online: 6 June 2023
Declarations
:
: All data collection followed HIPAA and insurance industry standards.
: This manuscript contains no individual person’s data in any form.
: TH and WM are employees and shareholders of Astellas Gene Therapies (formerly, Audentes Therapeutics). AHB has consulted and received compensation or honoraria from Astellas Gene Therapies, Biogen, F. Hoffman-La Roche AG, Kate Therapeutics, GLG Inc, and Guidepoint Global, he holds equity in KineaBio and Kate Therapeutics and is an inventor on a US patent describing a method for gene therapy of XLMTM. DF is an employee of IPM.ai, which received funding from Astellas Gene Therapies for this study analysis.